A study of the regional differences in propacetamol-related adverse events using VigiBase data of the World Health Organization
Abstract Upon withdrawal of propacetamol, an injectable formulation of the paracetamol prodrug, in Europe due to safety concerns, South Korea’s regulatory body requested a post-marketing surveillance study exploring its safety profile. We characterized regional disparities in adverse events (AE) ass...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-12-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-26211-0 |